Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects

Obesity

Volumn 15, Issue 7, 2007, Pages 1717-1731

  Astrup, Arne ^a,e   Greenway, Frank L ^b   Ling, Walter ^c   Pedicone, Lisa ^d   Lachowicz, Jean ^d   Strader, Catherine D ^d   Kwan, Rudolf ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Depression

Indexed keywords

BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; ECOPIPAM; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PATIENT SELECTION; PLACEBOS; WEIGHT LOSS;

EID: 34547954712     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.205     Document Type: Article

References (42)

1. York DA, Rossner S, Caterson I, et al. American Heart Association. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: group I: worldwide demographics of obesity. Circulation. 2004;110:e463-70.
2. Center for Disease Control and Prevention, National Center for Health Statistics. Prevalence of overweight and obesity among adults: United States, 1999-2002. Table 2. Ageadjusted prevalence of overweight and obesity among U.S. adults, age 20-74 years, http://www.cdc.gov/nchs/products/ pubs/pubd/hestats/obese/obse99.htm (Accessed December 31, 2006).
3. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obes Rev. 2005;6:5-7.
4. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-200.
5. Pisabarro R, Kaufmann P. Prevalence of obesity in Uruguay. Obes Rev. 2004;5:175-6.
6. Rashidi A, Mohammadpour-Ahranjani B, Vara MR, Karandish M. Prevalence of obesity in Iran. Obes Rev. 2005; 6:191-2.
7. Rguibi M, Belahsen R. Overweight and obesity among urban Sahraoui women of South Morocco. Ethn Dis. 2004;14:542-7.
8. Resnick HE, Valsania P, Halter JB, Lin X. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health. 2000;54: 596-602.
9. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8:605-19.
10. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141:1117-27.
11. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-7.
12. Hochberg MC, Lethbridge-Cejku M, Scott WW Jr, Reichle R, Plato CC, Tobin JD. The association of body weight, body fatness and body fat distribution with osteoarthritis of the knee: data from the Baltimore Longitudinal Study of Aging. J Rheumatol. 1995;22:488-93.
13. Astrup A. Treatment of obesity. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. 3rd ed. Chichester, UK: John Wiley & Sons; 2004, pp. 673-90.
14. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes Relat Metab Disord. 1989;13(Suppl 2):39-46.
15. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res. 2004;24: 165-205.
16. Sutton MA, Beninger RJ. Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors. Psychopharmacology (Berl). 1999;144: 95-110.
17. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann N Y Acad Sci. 1989;575:171-91.
18. Fetissov SO, Meguid MM, Sato T, Zhang LH. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am J Physiol Regul Integr Comp Physiol. 2002;283:R905-10.
19. Yu WZ, Silva RM, Sclafani A, Delamater AR, Bodnar RJ. Pharmacology of flavor preference conditioning in sham-feeding rats: effects of dopamine receptor antagonists. Pharmacol Biochem Behav. 2000;65:635-47.
20. El-Ghundi M, O'Dowd BF, Erclik M, George SR. Attenu ation of sucrose reinforcement in dopamine D1 receptor deficient mice. Eur J Neurosci. 2003;17:851-62.
21. Tice MA, Hashemi T, Taylor LA, Duffy RA, McQuade RD. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol Biochem Behav. 1994;49:567-71.
22. Romach MK, Glue P, Kampman K, et al. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry. 1999;56:1101-6.
23. Nann-Vernotica E, Donny EC, Bigelow GE, et al. Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology (Bed.) 2001;155:338-47.
24. Haney M, Ward AS, Foltin RW, Fischman MW. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology (Berl). 2001;155:330-7.
25. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004; 3:CD004094.
26. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
28. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XEN-DOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
29. Després J-P, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-34.
30. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci. 2004;24: 4393-400.
31. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med. 2003;163:2058-65.
32. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2003;158:1139-47.
33. Goldsmith SJ, Anger-Friedfeld K, Beren S, Rudolph D, Boeck M, Aronne L. Psychiatric illness in patients presenting for obesity treatment. Int J Eat Dis. 1992;12:63-71.
34. Wadden TA, Sarwer DB, Wonble LG, Foster GD, McGuckin BG, Schimmel A. Psychosocial aspects of obesity and obesity surgery. Surg Clin North Am. 2001;81: 1001-24.
35. Fabricatore AN, Wadden TA. Psychological functioning of obese individuals. Diabetes Spectr. 2003;16:245-52.
36. Carpenter KM, Hasin DS, Allison DB, Faith MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health. 2000;90:251-7.
37. Choban PS, Onyejekwe J, Burge JC, Flancbaum L. A health status assessment of the impact of weight loss following Roux-en-Y gastric bypass for clinically severe obesity. J Am Coll Surg. 1999;188:491-7.
38. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-56.
39. Chausmer AL, Smith BJ, Kelly RY, Griffiths RR. Cocainelike subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166). Behav Pharmacol. 2003;14:111-20.
40. Engström G, Alling C, Blennow K, Regnéll G, Träskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters: monamine metabolites in 120 suicide attempters and 47 controls. Eur Neuro-psychophamacol. 1999;9:399-405.
41. Ossowska G, Nowa G, Kata R, et al. Brain monoamine receptors in a chronic unpredictable stress model in rats. J Neural Transm. 2001;108:311-9.
42. Horvitz JC. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience. 2000; 96:651-6.